-
公开(公告)号：US20190290749A1
公开(公告)日：2019-09-26
申请号：US16345699
申请日：2017-10-30
申请人： EYEGENE INC.
发明人： Yang Je Cho , Kwangsung Kim , Na Gyong Lee , Shin Ae Park
IPC分类号： A61K39/12 , A61K39/002 , A61K39/39 , A61P31/12
摘要： The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.
-
公开(公告)号：US20140105868A1
公开(公告)日：2014-04-17
申请号：US14044692
申请日：2013-10-02
申请人： EYEGENE, INC.
发明人： Doo-Sik KIM , Yang-Je CHO , Won-Il YOO , Oh-Woong KWON , Jin-Wook JANG , Hyeong-Joon LIM , Soo-Mee KWON
摘要： A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.
摘要翻译： 在有需要的受试者中治疗血管相关疾病的方法包括向受试者施用具有序列Xaa-Gly-Asp的肽。 肽可以具有SEQ ID NO：1,2,4,6-10的序列。血管相关疾病可能是由血管壁的血液渗漏，血管损伤或血管生成异常引起的水肿和/或缺血。
-
公开(公告)号：US10918709B2
公开(公告)日：2021-02-16
申请号：US16345699
申请日：2017-10-30
申请人： EYEGENE INC.
发明人： Yang Je Cho , Kwangsung Kim , Na Gyong Lee , Shin Ae Park
IPC分类号： A61K39/12 , A61P31/12 , A61K39/39 , C08B37/00 , A61K31/739 , A61K39/002 , A61K39/00 , A61K39/295
摘要： The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.
-
4.发明申请公开(公告)号：US20150038405A1
公开(公告)日：2015-02-05
申请号：US14384646
申请日：2013-03-11
申请人： EYEGENE, INC.
发明人： Yang Je Cho , Jin Wook Jang , Hyeong Joon Lim
IPC分类号： C07K14/00
摘要： The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of SEQ ID NO: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and effectively reduces the formation of atherosclerotic plaques, thereby exhibiting efficacy in treating arteriosclerosis.
摘要翻译： 本发明提供了用于预防或治疗动脉硬化的药物组合物，其包含：药学有效量的包含SEQ ID NO：1的氨基酸序列的蛋白质; 和药学上可接受的载体。 本发明的组合物在肝脏或肾脏中没有显示毒性，并有效地减少动脉粥样硬化斑块的形成，从而显示治疗动脉硬化的功效。
-
公开(公告)号：US20240165222A1
公开(公告)日：2024-05-23
申请号：US18548080
申请日：2021-11-11
申请人： EYEGENE INC.
发明人： Yang Je CHO , Seok Hyun KIM , Kwangsung KIM
IPC分类号： A61K39/215 , A61K9/127 , A61K9/19 , A61P37/04
CPC分类号： A61K39/215 , A61K9/1272 , A61K9/19 , A61P37/04 , A61K2039/53
摘要： The present invention relates to a vaccine composition for preventing SARS-CoV-2, comprising mRNA encoding an S mutant antigen of SARS-CoV-2 virus, wherein a vaccine for preventing SARS-CoV-2 according to the present invention exhibits excellent stability and high immunogenicity in vivo, and the vaccine is thus easy to store and use, and excellent preventive effect thereof against COVID-19 can be expected.
-
公开(公告)号：US20240148897A1
公开(公告)日：2024-05-09
申请号：US18279689
申请日：2022-03-07
申请人： EYEGENE INC.
发明人： Yang Je CHO , Seok Hyun KIM , Kwangsung KIM , Shin Ae PARK
CPC分类号： A61K47/6911 , A61K8/14 , A61K9/1272 , A61K39/215 , A61K39/39 , A61K47/543 , A61K2039/55577
摘要： The present disclosure relates to a mRNA delivery composition comprising cationic lipid-based liposome. The mRNA delivery composition according to the present disclosure is superb in terms of storage stability and exhibits high intracellular delivery and expression rates in vivo and thus, can enhance the stability and efficiency of mRNA vaccines for cancer therapy or mRNA vaccines for prevention of viral infections.
-
公开(公告)号：US20220287970A1
公开(公告)日：2022-09-15
申请号：US17636319
申请日：2021-05-28
申请人： EYEGENE INC
发明人： Yang Je CHO , Na Gyong LEE , Kwangsung KIM , Shin Ae PARK , Sunyoung AHN
IPC分类号： A61K9/127 , A61P7/04 , A61K31/704
摘要： A cationic liposome having the effect of inhibition of red blood cell hemolysis induced by saponin is disclosed. More particularly, a composition for inhibiting red blood cell hemolysis by saponin comprising a cationic liposome containing an unsaturated lipid, a composition for immunity enhancement and a composition for drug delivery comprising the composition for inhibiting red blood cell hemolysis by saponin, and a drug delivery carrier and a drug-carrier complex comprising a cationic liposome containing an unsaturated lipid are disclosed.
Saponin exhibits a wide range of pharmacological and biological activities, such as anti-inflammatory activity, etc., including strong and effective immunological activity, and thus is effectively used medically and pharmaceutically, but has a disadvantage of causing hemolysis to red blood cells. Although saponin is generally used along with cholesterol, etc. to inhibit the hemolysis of saponin, it is confirmed herein that red blood cell hemolysis by saponin can be inhibited using a cationic liposome, which is more effective and economical in inhibiting the hemolysis of saponin. Therefore, saponin can be more usefully applied to the manufacture of immunity enhancers, drug delivery carriers, etc.-
公开(公告)号：US09290542B2
公开(公告)日：2016-03-22
申请号：US14384646
申请日：2013-03-11
申请人： EYEGENE, INC.
发明人： Yang Je Cho , Jin Wook Jang , Hyeong Joon Lim
摘要： The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of SEQ ID NO: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and effectively reduces the formation of atherosclerotic plaques, thereby exhibiting efficacy in treating arteriosclerosis.
摘要翻译： 本发明提供了用于预防或治疗动脉硬化的药物组合物，其包含：药学有效量的包含SEQ ID NO：1的氨基酸序列的蛋白质; 和药学上可接受的载体。 本发明的组合物在肝脏或肾脏中没有显示毒性，并有效地减少动脉粥样硬化斑块的形成，从而显示治疗动脉硬化的功效。
-
公开(公告)号：US20210353711A1
公开(公告)日：2021-11-18
申请号：US17286710
申请日：2019-10-17
申请人： EYEGENE INC.
发明人： Yang Je CHO , Hee Jin NAM
摘要： The present invention provides a pharmaceutical composition having an excellent anti-inflammatory effect, thereby enabling effective prevention or treatment of inflammatory diseases such as reperfusion injury, periodontitis, arthritis, pressure sore inflammation, wound inflammation or dermatitis, and provides an anti-inflammatory cosmetic composition to be used as a raw material of cosmetic products that can be used for various inflammatory skin diseases.
-
公开(公告)号：USRE48023E1
公开(公告)日：2020-06-02
申请号：US15158437
申请日：2016-05-18
申请人： EYEGENE INC.
发明人： Doo-Sik Kim , Yang-Je Cho , Won-Il Yoo , Oh-Woong Kwon , Jin-Wook Jang , Hyeong-Joon Lim , Soo-Mee Kwon
摘要： A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.019 秒)
